Clinical Trial Update: AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

Phase 2 trial of AMX0035 in amyotrophic lateral sclerosis completed; results were posted in August 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• AMX0035 (sodium phenylbutyrate and tauroursodeoxycholic acid)

Snippet

Sponsor: Amylyx Pharmaceuticals Inc. | Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-08-11